K J Metzner

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
    Claudia F Althaus
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Retrovirology 9:27. 2012
  2. ncbi A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication
    Peter M Huelsmann
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    BMC Biotechnol 11:4. 2011
  3. ncbi Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
  4. ncbi Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Germany
    J Clin Virol 50:156-61. 2011
  5. ncbi Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Infect Dis 48:239-47. 2009
  6. ncbi [Evolution and Diversity of HIV-1]
    K J Metzner
    Klinik für Infektionskrankheiten und Spitalhygiene, Universitatsspital Zurich
    Praxis (Bern 1994) 100:29-35. 2011
  7. ncbi Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
  8. ncbi Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients
    Karin J Metzner
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    AIDS 21:703-11. 2007
  9. ncbi Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo
    Kristina Allers
    Institute of Clinical and Moleculr Virology, University of Erlangen Nuremburg, Erlangen, Germany
    J Acquir Immune Defic Syndr 44:377-85. 2007
  10. ncbi The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro
    Daniel Drogan
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    Antiviral Res 86:312-5. 2010

Collaborators

Detail Information

Publications15

  1. ncbi Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
    Claudia F Althaus
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Retrovirology 9:27. 2012
    ..Thus, we applied a novel, sequence targeted enrichment strategy to capture HIV-1 derived sncRNAs in HIV-1 infected primary CD4+ T-lymphocytes and macrophages that allows a greater than 100-fold enrichment of low abundant sncRNAs...
  2. ncbi A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication
    Peter M Huelsmann
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    BMC Biotechnol 11:4. 2011
    ..We tested truncated Bid (tBid), a human pro-apoptotic protein that induces apoptosis very rapidly and efficiently, as suicide gene for gene therapy against HIV-1 infection...
  3. ncbi Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    J Infect Dis 201:1063-71. 2010
    ....
  4. ncbi Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Germany
    J Clin Virol 50:156-61. 2011
    ....
  5. ncbi Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Infect Dis 48:239-47. 2009
    ..Therefore, we evaluated the possible role of minority quasispecies of drug-resistant human immunodeficiency virus type 1, which are undetectable at baseline by population sequencing, with regard to early virological failure...
  6. ncbi [Evolution and Diversity of HIV-1]
    K J Metzner
    Klinik für Infektionskrankheiten und Spitalhygiene, Universitatsspital Zurich
    Praxis (Bern 1994) 100:29-35. 2011
    ....
  7. ncbi Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
    ..These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations...
  8. ncbi Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients
    Karin J Metzner
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    AIDS 21:703-11. 2007
    ..In this study, we wanted to determine whether drug-resistant viruses are already selected during viral decline within the first months of ART...
  9. ncbi Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo
    Kristina Allers
    Institute of Clinical and Moleculr Virology, University of Erlangen Nuremburg, Erlangen, Germany
    J Acquir Immune Defic Syndr 44:377-85. 2007
    ....
  10. ncbi The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro
    Daniel Drogan
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany
    Antiviral Res 86:312-5. 2010
    ..Mathematical modeling of the distinct rates of suppression of drug-sensitive viruses revealed an approximately 3-fold higher antiretroviral potency for FTC compared to 3TC...
  11. ncbi Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance
    Claudia F Althaus
    Division of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Virol Methods 165:151-60. 2010
    ..Thus, empirically validated novel principles of FH-probe design regarding conservation and qPCR-performance were identified, which complement and extend current rules for FH-probe design...
  12. ncbi Detection and significance of minority quasispecies of drug-resistant HIV-1
    Karin J Metzner
    Institute of Clinical and Molecular Virology, University of Erlangen-Nuremberg, Schlossgarten, Erlangen, Germany
    J HIV Ther 11:74-81. 2006
  13. ncbi Inhibition of drug-resistant HIV-1 by RNA interference
    Peter M Huelsmann
    University of Erlangen-Nuremberg, Institute of Clinical and Molecular Virology, Schlossgarten 4, D-91054 Erlangen, Germany
    Antiviral Res 69:1-8. 2006
    ..Taken together, these results demonstrate that RNA interference might be useful in the treatment of drug-resistant HIV-1 infection...
  14. ncbi Detection of minor populations of drug-resistant HIV-1 in acute seroconverters
    Karin J Metzner
    University of Erlangen Nuremberg, Institute of Clinical and Molecular Virology, Germany
    AIDS 19:1819-25. 2005
    ..As minor populations of drug-resistant HIV-1 could impact the efficiency of antiretroviral therapy, this study was performed to determine the prevalence of minor populations of drug-resistant HIV-1 in acute seroconverters...
  15. ncbi Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA
    Christian Hofmann
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    AIDS 22:1577-82. 2008
    ..Antigen-specific cytotoxic T lymphocytes can be generated by T-cell receptor transfer. This is commonly done by retroviral transduction, which is complicated and poses the threat of stable genetic alteration of autologous cells...